Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma

• Main Authors: Lan Gao (Author), Diksha Kaushik (Author), Brian A. Van Tine (Author), Matthew A. Ingham (Author), Steven Attia (Author), Christian F. Meyer (Author), Gary K. Schwartz (Author), Pius Maliakal (Author), John D. Baird (Author), Jiyuan Ma (Author), Rosemary Barrett (Author), Dhiren D'Silva (Author), Kylie O'Keefe (Author), Ronald Kong (Author)
• Format: Book
• Published: Wiley, 2024-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Unesbulin is being investigated in combination with dacarbazine (DTIC) as a potential therapeutic agent in patients with advanced leiomyosarcoma (LMS). This paper reports the pharmacokinetics (PK) of unesbulin, DTIC, and its unreactive surrogate metabolite 5‐aminoimidazole‐4‐carboxamide (AI...